PCT

franco Veneto (IT).

(75) Inventors/Applicants (for US only): RIGHETTO, Zefferino [IT/IT]; Via Roma, 122, I-30010 Camponogara (IT). BELLINI, Davide [IT/IT]; Via Sicilia, 32, I-31033 Castel-

(74) Agents: GUTMANN, Ernest et al.; Ernest Gutmann - Yves Plasseraud S.A., 3, rue Chauveau-Lagarde, F-75008 Paris

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: WO 95/24429 (11) International Publication Number: A1 C08B 37/00 (43) International Publication Date: 14 September 1995 (14.09.95) PCT/EP95/00932 (81) Designated States: CA, JP, US, European patent (AT, BE, CH, (21) International Application Number: DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). 13 March 1995 (13.03.95) (22) International Filing Date: Published With international search report. (30) Priority Data: Before the expiration of the time limit for amending the 11 March 1994 (11.03.94) IT PD94A000043 claims and to be republished in the event of the receipt of amendments. (71) Applicant (for all designated States except US): FIDIA ADVANCED BIOPOLYMERS S.R.L. [IT/IT]; Via De'Carpentieri, 3, I-72100 Brindisi (IT). (72) Inventors; and

(54) Title: HIGHLY REACTIVE ESTERS OF CARBOXY POLYSACCHARIDES AND NOVEL CARBOXY POLYSACCHARIDES DERIVED THEREFROM

(57) Abstract

PNSDCCID < WO 9524429A1 | >

Provided are active esters of carboxy polysaccharides and semisynthetic derivatives of carboxy polysaccharides, wherein all or part of the carboxy groups thereof are esterified with an aromatic alcohol, a substituted aromatic alcohol, an aromatic heterocyclic alcohol, a substituted aromatic heterocyclic alcohol, an N-hydroxylamine, or a combination thereof. Also provided is a process for producing such active esters. These active esters can be used for the preparation of modified carboxy polysaccharides or modified semisynthetic derivatives of such carboxy polysaccharides, in the form of esters, thioesters, or amides. Such active esters, modified polysaccharides, and modified semisynthetic derivatives of carboxy polysaccharides can be used in the biomedical and pharmaceutical fields to prepare, for example, cosmetic articles, health care articles, surgical articles, and diagnostic kits.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic	SD	Sudan
CG	Congo		of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SI	Slovenia
CI	Côte d'Ivoire	KZ	Kazakhstan	SK	Slovakia
CM	Cameroon	LI	Liechtenstein	SN	Senegal
CN	China	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
cz	Czech Republic	LV	Latvia	TJ	Tajikistan
DE	Germany	MC	Monaco	TT	Trinidad and Tobago
DK	Denmark	MID	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali	UZ	Uzbekistan
FR	France	MN	Mongolia	VN	Viet Nam
EK.	Cohen	34214	**************************************		

WO 95/24429 PCT/EP95/00932

HIGHLY REACTIVE ESTERS OF CARBOXY POLYSACCHARIDES AND NOVEL CARBOXY POLYSACCHARIDES DERIVED THEREFROM

BACKGROUND OF THE INVENTION

Field of the Invention

5

10

1.5

20

The present invention relates to active esters of carboxy polysaccharides and semisynthetic derivatives of such carboxy polysaccharides, wherein all or a part of the carboxy functions of the polysaccharides are esterified with alcohols of the aromatic, heterocyclic aromatic, or N-hydroxylamine series and, in the case of active partial esters, the remaining carboxy functions are salified with quaternary ammonium salts or metals. The present invention also relates to a method for the synthesis of said active esters starting with carboxy polysaccharides and their semisynthetic derivatives.

The present invention also relates to the use of such active esters as intermediates in the synthesis of modified carboxy polysaccharides and modified semisynthetic derivatives of carboxy polysaccharides, the modified polysaccharides and modified semisynthetic derivatives thereof per se, and the use of such modified polysaccharides and semisynthetic derivatives thereof to produce health care and surgical articles for use in the pharmaceutical and biomedical fields.

15

20

25

30

2

Description of Related Art

There are reports in the literature of methods for the synthesis and application of active esters for amino acids which comprise stable intermediates for use in the synthesis of peptides (see Fields, C.B. and Noble, R.L. (1990) <u>Int. J. Peptide Protein Res</u>. 35:161-214; Atherton, E. and Sheppard, R.C. (1989) in Solid Phase Peptide Synthesis, A Practical Approach, IRL Press, Oxford; M. Bodansky (1984) in Principles of Peptide Synthesis, Springer-Verlag, Berlin, Heidelberg). esters result in greater reactivity of the carboxy group in nucleophilic substitution reactions as the strongly electron-attracting group bound to the carbonyl carbon can be easily substituted with a nucleophile (sulfide, alcoholic hydroxyl) to produce thioesters, amine, amides, and esters under suitable reaction conditions, i.e., solvents, temperature, catalysts, etc. with aromatic, substituted aromatic, comatic heterocyclic, and substituted aromatic heterocyclic alcohols, and N-hydroxylamines, belong to this class of active esters.

SUMMARY OF THE INVENTION

The present invention provides a novel method for producing esters, amides, and thioesters of carboxy polysaccharides via the formation of active ester intermediates, and subsequent nucleophilic substitution at the carboxyl functions of the polysaccharides.

Apart from being used as intermediate products which are stable and easily stored, due to subsequent nucleophile substituion reactions, the active esters of carboxy polysaccharides and their semisynthetic derivatives can be used as reaction intermediates for the preparation of diagnostic kits as surfaces for the activation of proteins.

10

15

20

25

35

The production method is mainly based upon plasmacoating applied between the polymeric surface of the support, e.g., polystyrene, and the activated polysaccharide with the formation of stable bonds.

According to the intended diagnostic use, activated polysaccharide-based surface is treated with binds the that to polypeptide or protein polysaccharide by a nucleophilic substitution reaction. The treated material can therefore be used identify biochemical targets, such as antibodies or other polypeptides compatible with the molecules bound hyaluronic acid by spectrophotometry methods (ELISA). and (b) immunological laboratory equipment and dishes for the cultivation and regeneration of cells and tissues.

For example, the typical hydrophilic characteristics of hyaluronic acid, in association with suitable polymeric supports, make the active esters with varying degrees of substitution useful in the biomedical field for any use which requires the blocking on the surface of the support of proteins or peptides which must then be detected and quantified by spectrophotometry or immunoenzymatic methods.

Hyaluronic acid amides are useful for two distinct purposes:

- a) the slow, controlled release of natural hyaluronic acid as a result of the greater stability of the amide bond compared to the ester bond; and
- b) the controlled release of the substituting 30 group, the biological activity of which depends upon its nature.

The carboxy polysaccharides and semisynthetic derivatives thereof employed in the present invention are all known and described, for example, in U.S. Patents 4,851,521, 5,122,598, 5,300,493, 5,332,809, and 5,336,668; European Patent Application No. 93917681.4; EP 0 216 453, EP 0 251 905, EP 0 342 557, EP 0 518 710,

10

15

20

25

30

35

4

EP 0 603 264, and EP 0 605 478; and WO 93/06136 and WO 94/03499. Among these are glycosaminoglycans, alginic acid, gellan, carboxymethylcellulose, carboxymethylchitin, and carboxymethylamide. Of particular importance among the glycosaminoglycans is hyaluronic acid. Of semisynthetic derivatives the polysaccharides, salts thereof, especially quaternary ammonium salts, are particularly important. important semisynthetic derivatives useful in present invention are the partial esters of carboxy polysaccharides with aliphatic, araliphatic, heterocyclic and cycloaliphatic alcohols.

The methods of synthesis and applications of quaternary ammonium salts, in particular tetrabutylammonium salts, and carboxy polysaccharide esters with aliphatic, araliphatic, heterocyclic and cycloaliphatic alcohols, are described in the patent publications listed supra.

The stability and versatility of the present active esters of carboxy polysaccharides make these compounds useful in the synthesis of a variety of modified polysaccharides, in particular amide derivatives of such polysaccharides. Among such polysaccharide derivatives, those obtained by reaction of active esters with primary amines, amino acids, peptides, and proteins are particularly important.

Accordingly, it is an object of the present invention to provide an active ester of a carboxy polysaccharide or a semisynthetic derivative of a carboxy polysaccharide, wherein all or part of the carboxy groups thereof are esterified with an alcohol selected from the group consisting of an aromatic alcohol, a substituted aromatic alcohol, an aromatic heterocyclic alcohol. a substituted aromatic heterocyclic alcohol, an N-hydroxylamine, and combination thereof, wherein when only part of the carboxy groups of said carboxy polysaccharide or said

10

15

20

25

30

35

semisynthetic derivative of said carboxy polysaccharide are esterified, the remaining carboxy groups are salified with a member selected from the group consisting of a quaternary ammonium salt, an alkaline metal, an alkaline earth metal, and a combination thereof.

Another object of the present invention is to provide a process for producing an active ester as described above, comprising reacting a tetraalkylammonium salt of a carboxy polysaccharide or a semisynthetic derivative of a carboxy polysaccharide with a reactive derivative of an alcohol to be bound to the carboxyl groups thereof in an aprotic solvent at a temperature of between about 0 and about 60°C.

Another object of the present invention is the use of such active esters for the preparation of a modified carboxy polysaccharide or a modified semisynthetic derivative of a carboxy polysaccharide, wherein said modified carboxy polysaccharide or said modified semisynthetic derivative of a carboxy polysaccharide is an ester, thioester, or amide.

A further object of the present invention is a modified carboxy polysaccharide, or a modified semisynthetic derivative of a carboxy polysaccharide, prepared from such active esters.

A still further object of the present invention is the use of such active esters, modified polysaccharides, and modified semisynthetic derivatives of such polysaccharides in the biomedical and pharmaceutical fields to prepare, for example, cosmetic articles, health care articles, surgical articles, and diagnostic kits.

Further scope of the applicability of the present invention will become adpparent from the detailed description provided below. It should be understood, however, that the following detailed description and specific examples, while indicating preferred

10

15

30

A L LAGONNEAG

6

embodiments of the present invention, are given by way of illustration only since various changes and modifications within the spirit and scope of the present invention will become apparent to those skilled in the art from this detailed description.

DETAILED DESCRIPTION OF THE INVENTION

The following detailed description of the present invention is provided to aid those skilled in the art in practicing the same. Even so, the following detailed description should not be construed to unduly limit the present invention, as modifications and variations in the embodiments discussed herein may be made by those of ordinary skill in the art without departing from the spirit or scope of the present inventive discovery.

The contents of each of the references discussed herein are herein incorporated by reference in their entirety.

Alcohols Useful In Preparing Active Carboxy Polysaccharide Esters

The active esters of carboxy polysaccharides and semisynthetic derivatives thereof of the present invention are those with alcohols of the aromatic, substituted aromatic, aromatic heterocyclic, substituted aromatic heterocyclic, and N-hydroxyl amine type.

These alcohols include, but are not limited to:

pentafluorophenol,
pentachlorophenol,
trichlorophenol,

p-nitrophenol, 2,4-dinitrophenol,
2-hydroxypyridine, 3-hydroxypyridine,

3,4-dihydro-4-oxobenzotriazine-3-ol,

4-hydroxy-2,5-diphenyl-3(2H)-thiophenone-1, 1-dioxide,

3-phenyl-1-(p-nitrophenyl)-2-pyrazoline-5-one,

3-methyl-1-(p-nitrophenyl)-2-pyrazoline-5-one,

PCT/EP95/00932

5

10

15

20

25

30

35

7

N-hydroxysuccinimide, and N-hydroxyphthalimide.

Esters

The most interesting of the esters that can be obtained include the p-nitrophenyl ester, the pentafluorophenyl ester, the 4-dihydro-4-oxobenzotriazine-3-yl ester, and the N-succinimidyl ester.

The active esters can be total, i.e., all the carboxy functions of the polysaccharide are employed in the formation of the active ester, or partial, i.e., only part of the carboxy functions are involved in the formation of the active ester.

In the case of partial active esters, the carboxy functions not involved in the formation of the active ester are in the form of a salt, in particular the tetrabutylammonium salt. Formation of active esters of semisynthetic derivatives of carboxy polysaccharides involves reaction at the carboxyl groups not already covalently bound therein.

Carboxy Polysaccharides

The carboxy polysaccharides that can be employed as substrates for the synthesis of active esters are those already known and described, including naturally occurring polysaccharides of animal or vegetable origin, and semisynthetic derivatives thereof. Particularly useful carboxy polysaccharides include, but are not limited to, glycosaminoglycans, e.g., hyaluronic acid, as well as alginic acid, gellan, carboxymethylcellulose, carboxymethylchitin, and carboxymethylamide.

Of the semisynthetic derivatives, carboxy polysaccharide salts, in particular quaternary ammonium salts such as tetraalkyl ammonium salts, for example, tetrabutylammonium salt, is preferred.

15

20

25

30

35

As semisynthetic carboxy polysaccharide starting materials, it is also possible to use partial esters of said polysaccharides, in particular esters with alcohols of the aliphatic, araliphatic, cycloaliphatic, and heterocyclic series. Of these, the partial esters with aliphatic alcohols having between 2 and 34 carbon atoms, in particular ethanol, and partial esters with alcohols of the araliphatic series, in particular benzyl alcohol, are preferred. The partial esters of hyaluronic acid known as HYAFF, described in U.S. Patents 4,851,521, 4,965,353, and 5,202,431, typify such partial esters.

Surprisingly, active esters of carboxy polysaccharides and their semisynthetic derivatives have been obtained without any undesired side reactions, such as the formation of intra- and inter-chain bridges, which lead to the phenomenon known as auto-crosslinking.

Reaction Conditions

The formation reaction of the active esters starting from carboxy polysaccharides or semisynthetic derivatives thereof, wherein all or part of the carboxy functions are salified with a tetraalkylammonium salt, occurs by first-order kinetics.

Activation of the carbonyl residues is achieved by classic stoichiometric methods, and the percentage of active ester formed depends upon the quantity (in mEq) of alcohol or N-hydroxylamine added to the carboxy polysaccharide tetrabutylammonium salt. Temperature does not seem to be a significant determinant factor in the esterification yield.

The reaction is conducted by adding esterification reagent to a solution of the carboxy which is in the form of polysaccharide tetraalkylammonium, e.g., tetrabutylammonium, salt, or to a solution of the partial carboxy polysaccharide ester, in which case the remaining carboxy functions are in the form of tetraalkyl, e.g., tetrabutylammonium,

10

20

25

30

9

salts, in an aprotic solvent such as dimethylsulfoxide, N-methylpyrrolidone, or N,N'-dimethylformamide. The reaction temperature can be in the range of from about 0°C to about 60°C, preferably about 25°C to about 40°C, depending upon the reagent used.

Reactive Derivatives

The reactive derivatives that can be used for the synthesis of the active esters are aryl trifluoro-acetates, such as p-nitrophenyl trifluoroacetate and pentafluorophenyl trifluoroacetate; aryl phosphites; aryl sulfites, such as di-penta-fluorophenyl sulfite; carbonates, such as di-(N-succinimidyl)carbonate and 4,6-diphenylthiene-[3,4-d]-1,3-dioxol-2-one5,5-dioxide (TDO carbonate, or Steglich's reagent).

15 New Carboxy Polysaccharide Derivatives Derived From Active Esters

The resulting active carboxy polyssacharide esters can be advantageously employed in the synthesis of new carboxy polysaccharide derivatives as these active esters exhibit high reactivity in nucleophilic substitution reactions at the carbonyl carbons of activated carboxyl groups.

Nucleophiles

Nucleophiles that can be used in such reactions include, but are not limited to, primary amines, amino acids, peptides, proteins, mercaptans, and alcohols.

Useful primary amines include aliphatic amines, araliphatic amines, and substituted derivatives of said amines, such as aliphatic amines containing alkyl chains substituted with halogen atoms, in particular perfluoroamines.

Among the useful primary amines are ethylamine, n-propylamine, isopropylamine, N-butylamine,

15

20

25

30

35

N-heptylamine, benzylamine, N-ethyl aminobenzene, benzedrine, benzocaine, and N-pentylamine.

The amino acids that can be employed include all known amino acids, and the same is true of peptides and proteins.

Among the amino acids that can be particularly mentioned are phenylalanine, glycine, serine, leucine, tryptophan, aspartic acid, arginine, and serine benzyl ester.

Among the polypeptides are Phe-Val-Glu-Tyr-Leu, Gly-Arg-Gly-Asp-Ser-Tyr, Gly-Arg-Gly-Asp-Val-Tyr, and Gly-Arg-Gly-Glu-Ser-Tyr.

Among the proteins are albumin and calcitonin.

Among the mercaptans are thioethane, thiofuran, thiophenol, thioanisol, thioglycerol, and 5-thioglucose.

Useful alcohols include those disclosed in U.S. Patents 4,851,521, 4,965,353, and 5,202,431. These patents also disclose other primary amines, amino acids, peptides, proteins, and mercaptans useful in the present invention.

Properties of the active esters of carboxy polysaccharides and their semisynthetic derivatives that are extremely useful include their high reactivity and selectivity with respect to amines compared to that with alcohols and mercaptans in nucleophilic substitution reactions. This leads to a significant decrease in undesirable secondary reactions in the synthesis of new, modified polysaccharides, which occur, for example, when condensing agents such as dicyclohexylcarbodiimide, N-hydroxy-benzotriazol, etc., are employed, or due to the presence of functional groups such as amino or hydroxy groups, for example.

The new modified polysaccharides produced from active esters of the present invention can be used in the preparation of health care and surgical articles for internal or external use, such as microcapsules, microspheres, threads, films, gauzes, sponges, etc., as

10

described in U.S. Patents 4,851,521, 4,965,353, and 5,202,431. These can be advantageously employed in the biomedical and pharmaceutical fields such as, for example, in the areas of wound care, tissue healing and repair, prevention of tissue adhesion, and in controlled-release systems for biologically active substances such as amino acids, peptides, and proteins.

While the Examples presented below describe the formation of various derivatives of hyaluronic acid, the same methods can be employed with the other carboxy polysaccharides of the present invention, such as alginic acid, gellan, carboxymethylcellulose, carboxymethylchitin, carboxymethylamide, etc.

Example 1

Preparation of a pentafluorophenyl partial ester
of hyaluronic acid tetrabutylammonium salt
-5% of the carboxy groups are involved
in the formation of the active ester95% of the carboxy groups are in the form of
tetrabutylammonium salt

6.2 grams of hyaluronic acid tetrabutylammonium salt with a molecular weight of 180,000 Daltons, corresponding to 10 mEq of a monomeric unit, are solubilized in 310 ml of N-methylpyrrolidone at 25°C. This solution is shaken while 0.040 ml of pyridine (0.5 25 are added, followed by 0.088 ml of pentafluorophenyl trifluoroacetate (0.5 mEq). The reaction mixture is shaken at 25°C for 1 hour, after which the product is precipitated by the addition of 2 30 liters of ethyl acetate. The precipitate is filtered and washed twice with 500 ml of ethyl acetate, and then vacuum-dried for 24 hours at 30°C.

6.15 grams of product with the desired titer are thus obtained. Quantitative analysis of the percentage of esterification was performed by gas chromatography to

25

determine the pentafluorophenol content after alkaline hydrolysis of the ester.

Example 2

Preparation of a pentafluorophenyl partial ester of hyaluronic acid tetrabutylammonium salt -10% of the carboxy groups are involved in the formation of the active ester90% of the carboxy groups are in the form of tetrabutylammonium salt

- 10 6.2 grams of hyaluronic acid tetrabutylammonium salt with a molecular weight of 160,000 Daltons, corresponding to 10 mEq of a monomeric unit, solubilized in 310 ml of N-methylpyrrolidone at 25°C. This solution is shaken while 0.080 ml of pyridine (1 15 mEq) and then 0.176 ml of pentafluorophenyl trifluoroacetate (1 mEg) are added to it. The reaction mixture is shaken at 25°C for 1 hour, after which the product is precipitated by the addition of 2 liters of ethyl acetate. The precipitate is filtered and washed 20 twice with 500 ml of ethyl acetate, and then vacuum-dried for 24 hours at 30°C.
 - 6.12 grams of the product with the desired titer are obtained. Quantitative analysis of the percentage of esterification was performed by gas chromatography to determine the pentafluorophenol content after alkaline hydrolysis of the ester.

10

15

30

13

Example 3

Preparation of a pentafluorophenyl partial ester of hyaluronic acid tetrabutylammonium salt -25% of the carboxy groups are involved in the formation of the active ester75% of the carboxy groups are in the form of tetrabutylammonium salt

- 6.2 grams of hyaluronic acid tetrabutylammonium salt with a molecular weight of 120,000 Daltons, corresponding to 10 mEq of a monomeric unit, are solubilized in 310 ml of N-methylpyrrolidone at 25°C. This solution is shaken while 0.200 ml of pyridine (2.5 mEa) and then 0.440 ml of pentafluorophenyl trifluoroacetate (2.5 mEq) are added to it. reaction mixture is shaken at 25°C for 1 hour, after which the product is precipitated by the addition of 2 liters of ethyl acetate. The precipitate is filtered and washed twice with 500 ml of ethyl acetate, and then vacuum-dried for 24 hours at 30°C.
- 20 6.01 gr of the product with the desired titer are thus obtained. Quantitative analysis of the percentage of esterification was performed by gas chromatography to determine the pentafluorophenol content after alkaline hydrolysis of the ester.

25 Example 4

Preparation of a pentafluorophenyl partial ester
of hyaluronic acid tetrabutylammonium salt
-50% of the carboxy groups are involved
in the formation of the active ester50% of the carboxy groups are in the form of
tetrabutylammonium salt

6.2 grams of hyaluronic acid tetrabutylammonium salt with a molecular weight of 80,000 Daltons, corresponding to 10 mEq of a monomeric unit, are

25

30

solubilized in 310 ml of N-methylpyrrolidone at 25°C. This solution is shaken while 0.400 ml of pyridine (5 pentafluoophenyl and then 0.880 ml of trifluoroacetate (5 mEq) are added to it. The reaction mixture is shaken at 25°C for 1 hour, after which the product is precipitated by the addition of 2 liters of ethyl acetate. The precipitate is filtered and washed with 500 ml of ethyl acetate, and then vacuum-dried for 24 hours at 30°C.

5.82 grams of the product with the desired titer are obtained. Quantitative analysis of the percentage of esterification was performed by gas chromatography to determine the pentafluorophenol content after alkaline hydrolysis of the ester.

15 Example 5

Preparation of a pentafluorophenyl partial ester of hyaluronic acid tetrabutylammonium salt -75% of the carboxy groups are involved in the formation of the active ester25% of the carboxy groups are in the form of tetrabutylammonium salt

- 6.2 grams of hyaluronic acid tetrabutylammonium salt with a molecular weight of 400,000 Daltons, corresponding to 10 mEg of a monomeric unit, solubilized in 310 ml of N-methylpyrrolidone at 25°C. This solution is shaken while 0.600 ml of pyridine (7.5 then 1.32 ml of pentafluorophenyl trifluoroacetate (7.5 mEq) are added to it. reaction mixture is shaken at 25°C for 1 hour, after which the product is precipitated by the addition of 2 liters of ethyl acetate. The precipitate is filtered and washed twice with 500 ml of ethyl acetate, and then vacuum-dried for 24 hours at 30°C.
- 5.62 grams of the product with the desired titer 35 are obtained. Quantitative analysis of the percentage of

esterification was performed by gas chromatography to determine the pentafluorophenol content after alkaline hydrolysis of the ester.

Example 6

Preparation of the pentafluorophenyl total ester of hyaluronic acid - 100% of the carboxy groups are involved in the formation of the active ester

- 6.2 grams of hyaluronic acid tetrabutylammonium salt with a molecular weight of 180,000 Daltons, 10 corresponding to 10 mEq of a monomeric unit, are solubilized in 310 ml of N-methylpyrrolidone at 25°C. This solution is shaken while 0.800 ml of pyridine (10 pentafluorophenyl and then 1.760 ml oftrifluoroacetate (10 mEq) are added to it. The reaction 15 mixture is shaken at 25°C for 1 hour, after which the product is precipitated by the addition of 2 liters of ethyl acetate. The precipitate is filtered and washed twice with 500 ml of ethyl acetate, and vacuum-dried for 24 hours at 30°C.
- 5.44 grams of the product with the desired titer are obtained. Quantitative analysis of the percentage of esterification was performed by gas chromatography to determine the pentafluorophenol content after alkaline hydrolysis of the ester.

25 Example 7

Preparation of a 4-nitrophenyl partial ester of
hyaluronic acid tetrabutylammonium salt
-25% of the carboxy groups are involved
in the formation of the active ester75% of the carboxy groups are in the form of

75% of the carboxy groups are in the form of tetrabutylammonium salt

6.2 grams of hyaluronic acid tetrabutylammonium salt with a molecular weight of 120,000 Daltons,

15

20

corresponding to 10 mEq of a monomeric unit, are solubilized in 310 ml of dimethylsulfoxide at 25°C. This solution is shaken while 0.200 ml of pyridine (2.5 mEq) and then 0.59 ml of 4-nitrophenyl trifluoroacetate solubilized in 1 ml of dimethylsulfoxide (2.5 mEq) are added to it. The reaction mixture is shaken at 25°C for 1 hour, after which the product is precipitated by the addition of 2 liters of ethyl acetate. The precipitate is filtered and washed twice with 500 ml of ethyl acetate, and then vacuum-dried for 24 hours at 30°C.

5.8 grams of the product with the desired titer are thus obtained. Quantitative analysis of the percentage of esterification was performed by liquid chromatography to determine the 4-nitrophenol content after alkaline hydrolysis of the ester.

Example 8

Preparation of a partial ester of hyaluronic acid tetrabutylammonium salt with

4-hydroxy-2,5-diphenyl-3(2H)-thiophenone-1,1-dioxide
-50% of the carboxy groups are involved in the
formation of the active ester - 50% of the carboxy
groups are in the form of tetrabutylammonium salt

6.2 grams of hyaluronic acid tetrabutylammonium salt with a molecular weight of 800,000 Daltons, 25 corresponding to 10 mEg of a monomeric unit, are solubilized in 310 ml of N-methylsulfoxide at 25°C. solution is while shaken 1.63 grams 4,6-diphenylthiene-[3,4-d]-1,3-dioxol-2-one 5,5-dioxide (Steglich's reagent) solubilized in 5 30 dimethylsulfoxide (5 mEq) are added to it. The reaction mixture is shaken at 25°C for 30 minutes, after which the product is precipitated by the addition of 2 liters of ethyl acetate. The precipitate is filtered and washed twice with 500 ml of ethyl acetate, and then 35 vacuum-dried for 24 hours at 30°C.

6.39 grams of the product with the desired titer are thus obtained. Quantitative analysis of the percentage of esterification was performed by liquid chromatography to determine the

4-hydroxy-2,5-diphenyl-3(2H)-thiophenone-1,1-dioxide content after alkaline hydrolysis of the ester.

Example 9

Preparation of a pentafluorophenyl partial ester of alginic acid tetrabutylammonium salt -20% of the carboxy groups are

involved in the formation of the active ester
- 80% of the carboxy groups are in the

form of tetrabutylammonium salt

- 4.17 grams of alginic acid tetrabutylammonium salt а molecular weight of 100,000 Daltons, 15 with corresponding to 10 mEg of a monomeric unit, are solubilized in 210 ml of N-methylpyrrolidone at 25°C. This solution is shaken while 0.160 ml of pyridine (2 pentafluorophenyl mEq) and then 0.352 ml of trifluoroacetate (2 mEq) are added to it. The reaction 20 mixture is shaken at 25°C for 1 hour, after which the product is precipitated by the addition of 2 liters of ethyl acetate. The precipitate is filtered and washed twice with 500 ml of ethyl acetate, and then vacuumdried for 24 hours at 30°C. 25
 - 4.04 grams of the product with the desired titer are thus obtained. Quantitative analysis of the percentage of esterification was performed by gas chromatography to determine the pentafluorophenol content after alkaline hydrolysis of the ester.

25

18

Example 10

Preparation of a pentafluorophenyl partial ester
of HYAFF 7p50 (50% ethyl ester of hyaluronic acid)
tetrabutylammonium salt - 25% of the carboxy groups
are involved in the formation of the
active ester - 50% of the carboxy groups
are esterified with ethanol - 25% of
the carboxy groups are in the form of
tetrabutylammonium salt

10 5.2 grams of HYAFF 7p50 tetrabutylammonium salt molecular weight of 170,000 а Daltons. corresponding to 10 mEg of a monomeric unit, are solubilized in 260 ml of N-methylpyrrolidone at 25°C. This solution is shaken while 0.200 ml of pyridine (2.5 15 mEq) and then 0.440 ml pentafluorophenyl of trifluoroacetate (2.5 mEq) are added to it. The reaction mixture is shaken at 25°C for 1 hour, after which the product is precipitated by the addition of 2 liters of ethyl acetate. The precipitate is filtered 20 and washed twice with 500 ml of ethyl acetate, and then vacuum-dried for 24 hours at 30°C.

5 grams of the product with the desired titer are thus obtained. Quantitative analysis of the percentage of esterification was performed by gas chromatography to determine the pentafluorophenol content after alkaline hydrolysis of the ester.

25

19

Example 11

Preparation of a pentafluorophenyl ester of HYAFF 11p75

(75% benzyl ester of hyaluronic acid)

tetrabutylammonium salt - 25% of the carboxy groups are involved in the formation of the active ester75% of the carboxy groups are esterified with benzyl alcohol

- 5.07 grams of HYAFF 11p75 tetrabutylammonium salt 10 with a molecular weight of 120,000 Daltons, corresponding to 10 mEq of a monomeric unit, are solubilized in 260 ml of N-methylpyrrolidone at 25°C. This solution is shaken while 0.200 ml of pyridine (2.5 mEq) and then 0.440 ml of pentafluorophenyl 15 trifluoroacetate (2.5 mEq) are added to it. reaction mixture is shaken at 25°C for 1 hour, after which the product is precipitated by the addition of 2 liters of ethyl acetate. The precipitate is filtered and washed twice with 500 ml of ethyl acetate, and then 20 vacuum-dried for 24 hours at 30°C.
 - 4.8 grams of the product with the desired titer are thus obtained. Quantitative analysis of the percentage of esterification was performed by gas chromatography to determine the pentafluorophenol content after alkaline hydrolysis of the ester.

Example 12

Preparation of the N-ethyl partial amide of hyaluronic acid sodium salt -10% of the carboxy functions

30 <u>are transformed into N-ethyl amides-</u>

90% of the carboxy functions are salified with sodium

6.13 grams of the active ester obtained according to Example 2, corresponding to 10 mEq of a monomeric unit, are solubilized in 305 ml of N-methylpyrrolidone

at 25°C. This solution is shaken while 66 μ l of ethylamine (1 mEq) are added to it. The reaction mixture is shaken for 2 hours, after which 00 ml of a 2% solution of sodium chloride in deionized water are added The addition of 800 ml of acetone to this reaction mixture causes the formation of a precipitate which is filtered and washed three times with 100 ml of acetone/water 5:1, three times with 100 ml of acetone, and which is lastly vacuum-dried for 24 hours at 30°C. 10 4.0 grams of the desired product are thus obtained. Quantitative analysis of the amide groups was performed to determine the ethylamine content after alkaline hydrolysis.

Example 13

Preparation of the partial N-benzyl amide of 15 hyaluronic acid sodium salt -50% of the carboxy functions are transformed into N-benzyl amides-50% of the carboxy functions are salified with sodium

- 20 5.83 grams of the active ester obtained according to Example 4, corresponding to 10 mEq of a monomeric unit, are solubilized in 290 ml of N-methylpyrrolidone at 25°C. This solution is shaken while 5.46 ml of benzylamine (5 mEg) are added to it. The reaction 25 mixture is shaken for 2 hours, after which 100 ml of a solution of sodium chloride in deionized water are added to it. The addition of 800 ml of acetone to this reaction mixture causes the formation of a precipitate which is filtered and washed three times with 100 ml of 30 acetone/water 5:1, three times with 100 ml of acetone, and which is lastly vacuum-dried for 24 hours at 30°C.
 - 4.3 grams of the desired product are thus obtained. Quantitative analysis of the amide groups was performed to determine the benzylamine content after alkaline hydrolysis.
- 35

10

15

20

25

21

Example 14

Synthesis of an amide derivative of hyaluronic acid with arginine - 100% of the carboxy functions are transformed into amides of hyaluronic acid with arginine

5.45 grams of the active ester obtained according to Example 6, corresponding to 10 mEq of a monomeric unit, are solubilized in 270 ml of N-methyl pyrrolidone at 25°C. This solution is shaken while 1.74 gr of D-arginine (10 mEq) solubilized in 10 ml of N-methyl pyrrolidone are added to it. This solution is shaken for 2 hours, after which 800 ml of acetone are added to it. This causes the formation of a precipitate which is filtered, washed three times with 100 ml of acetone, and then vacuum dried for 24 hours at 30°C.

5.35 grams of the desired product are thus obtained. Quantitative analysis of the amide groups is performed to determine the arginine content after acid hydrolysis in 6N hydrochloric acid (amino acid analysis).

Example 15

Synthesis of a derivative of HYAFF 7p50 (50% ethyl ester of hyaluronic acid) containing a peptide having the sequence

H--Arq-Gly-Asp-OH

-50% of the carboxy functions are esterified with
ethanol - 25% of the carboxy functions are transformed
into amides of hyaluronic acid with the peptide25% of the carboxy functions are salified with sodium

30 The tripeptide known as RGD (arginine-glycine-aspartic acid) is the minimal cell-recognizable sequence in many adhesive plasma and extracellular matrix proteins. For example, the RGD tripeptide sequence has been found in vitronectin, fibronectin, von Willebrand

10

15

20

factor, fibrinogen and collagens, and this tripeptide has been shown to play a crucial role in mediating cell attachment and subsequent cell spreading.

RGD-containing peptides are therefore of interest in the development of novel biomaterials that may improve long-term endothelial cell attachment and growth.

- 4.95 grams of the active ester obtained according to Example 10, corresponding to 10 mEq of a monomeric unit, are solubilized in 250 ml of N-methyl pyrrolidone at 25°C. This solution is shaken while 1.08 gr of a peptide having the sequence H-Arg-Gly-Asp-OH (2.5 mEq) solubilized in 10 ml of N-methyl pyrrolidone are added This solution is shaken for 2 hours, after which 100 ml of a 2% solution of sodium chloride in deionized The addition of 800 ml of water are added to it. acetone to this reaction mixture causes the formation of -a-precipitate which is filtered, washed three times with 100 ml of acetone/water 5:1, three times with 100 ml of acetone, and which is then vacuum-dried for 24 hours at 30°C.
- 4.8 grams of the desired product are thus obtained. Quantitative determination of the amide groups is performed analysing the amino acid content.

25 Example 16

Synthesis of a derivative of HYAFF 11p75 (75% benzyl ester of hyaluronic acid) containing a peptide having the sequence H-Gly-Pro-Arg-OH

- 30 -75% of the carboxy functions are esterified with benzyl alcohol 25% of the carboxy functions are transformed into amides of hyaluronic acid with the peptide
- 4.8 grams of the active ester obtained according to 35 Example 11, corresponding to 10 mEq of a monomeric unit,

10

15

20

25

30

are solubilized in 240 ml of N-methyl pyrrolidone at 25°C. This solution is shaken while 0.82 grams of the peptide having the sequence H-Gly-Pro-Arg-OH (2.5 mEq) solubilized in 5 ml of N-methyl pyrrolidone are added to it. This solution is shaken for 2 hours, after which 100 ml of a 2% solution of sodium chloride in deionized water are added to it. The addition of 800 ml of acetone to this reaction mixture causes the formation of a precipitate which is filtered, washed three times with 100 ml of acetone/water 5:1, three times with 100 ml of acetone, and which is then vacuum-dried for 24 hours at 30°C.

5.2 grams of the desired product are thus obtained. Quantitative determination of the amide groups is performed analysing the amino acid content.

Example 17

Preparation of a spongy material made with the HYAFF 7p50 (50% ethyl ester of hyaluronic acid) containing a peptide having the sequence H-Arg-Gly-Asp-OH

4 grams of the derivative of HYAFF 7p50 containing a peptide having the sequence H-Arg-Gly-Asp-OH (described in Example 15) are solubilized in 120 ml of dimethylsulfoxide. The solution is filtered and poured onto a 3 x 4 cm steel dish. The dish is placed in a controlled environment at 25°C saturated with water vapour, which acts as a coagulant. A gelatinous slab is thus obtained which is cut into pieces measuring 1 x 1 cm.

These pieces are immersed in 2 liters of a 5% aqueous solution of NaCl. This material is freeze-dried, producing a spongy material which is then washed three times with 1 liter of distilled water to eliminate the sodium chloride incorporated in it.

Pieces of spongy material measuring 0.9 x 0.9 cm and 4 mm thick are thus obtained.

Example 18

Preparation of microspheres produced from HYAFF 11p75 (75% benzyl ester of hyaluronic acid) containing a peptide having the sequence H-Gly-Pro-Arg-OH, described in Example 16

The derivative of HYAFF 11p75 containing the peptide having the sequence H-Gly-Pro-Arg-OH, described in Example 16, is solubilized in 50 ml of dimethyl-10 sulfoxide at a concentration of 7% (w/v). 800 ml of a mixture of highly viscous mineral oil containing ARLACEL, a non-ionic surfactant, at a concentration of 1% (w/v), is prepared separately. The latter mixture is while the HYAFF 11p75 peptide derivative-15 shaken containing colution is added to it. An emulsion is formed, to which 2.5 liters of ethyl acetate are added. The ethyl acetate mixes with the emulsion phase, but the peptide derivative is insoluble in it. The suspension 20 thus obtained is filtered, and the resulting microspheres are washed with 6 liters of N-hexane. mean particle size of the microspheres is 15 μ m.

Example 19

Preparation of the partial N-propyl amide of 25 hyaluronic acid sodium salt - 50% of the carboxy functions are transformed into N-propyl amide 50% of the carboxy functions are salified with sodium

5.83 grams of the active ester obtained as in Example 4 corresponding to 10 mEq of a monomeric unit are solubilized in 290 ml of N-methylpyrrolidone at 25° C. To this solution are added, while stirring, 0.41 ml of N-propylamine (5 mEq). The mixture is stirred for 2 hours and then 100 ml of a 2% solution of sodium

chloride in deionized water are added. The addition to this reaction mixture of 800 ml of acetone causes the formation of a precipitate, which is filtered and washed three times with 100 ml of acetone and then vacuum-dried for 24 hours at 30°C.

4.2 grams of the desired product are thus obtained. Quantitative determination of the amide groups is performed by analysing the N-propylamine content after alkaline hydrolysis.

10 Example 20

Preparation of an amide derivative of hyaluronic acid with glycine - 50% of the carboxy functions are transformed into glycinamides - 50% of the carboxy functions are salified with sodium

- Example 4 corresponding to 10 mEq of a monomeric unit are solubilized in 290 ml of N-methylpyrrolidone at 25°C. To this solution are added, with stirring, 0.375 grams of glycine. The mixture is stirred for 2 hours and then 100 ml of a 2% solution of sodium chloride in deionized water are added. The addition to this reaction mixture of 800 ml of acetone causes the formation of a precipitate, which is filtered and washed three times with 100 ml of acetone and then vacuum-dried for 24 hours at 30°C.
 - 4.3 grams of the desired product are thus obtained. Quantitative determination of the amide groups is performed by analysing the glycine content after acid hydrolysis in 6N hydrochloric acid (amino acid analysis).

25

30

26

Example 21

Preparation of an amide derivative of hyaluronic acid with lysine - 100% of the carboxy functions are transformed into hyaluronic acid amides with lysine

5 5.45 grams of the active ester obtained as in Example 6 corresponding to 10 mEq of a monomeric unit are solubilized in 270 ml of N-methylpyrrolidone at 25°C. To this solution are added, with stirring, 1.46 grams of lysine. The mixture is stirred for 2 hours and then 100 ml of a 2% solution of sodium chloride in deionized water are added. The addition to this reaction mixture of 800 ml of acetone causes the formation of a precipitate, which is filtered and washed three times with 100 ml of acetone and then vacuum-dried for 24 hours at 30°C.

5.0 grams of the desired product are thus obtained. Quantitative determination of the amide groups is performed by analysing the lysine content after acid hydrolysis in 6N hydrochloric acid (amino acid analysis).

Example 22

Preparation of an amide derivative of hyaluronic acid with serine benzyl ester 10% of the carboxy functions are transformed into hyaluronic acid amides with serine benzyl ester 90% of the carboxy functions are salified with sodium

6.13 grams of the active ester obtained as in Example 2 corresponding to 10 mEq of a monomeric unit are solubilized in 305 ml of N-methylpyrrolidone at 25°C. To this solution are added, with stirring, 0.194 grams of serine benzyl ester. The mixture is stirred for 2 hours and then 100 ml of a 2% solution of sodium chloride in deionized water are added. The addition to this reaction mixture of 800 ml of acetone causes the

15

20

25

formation of a precipitate, which is filtered and washed three times with 100 ml of acetone and then vacuum-dried for 24 hours at 30°C.

4.5 grams of the desired product are thus obtained. Quantitative determination of the amide groups is performed by analysing the serine content after acid hydrolysis in 6N hydrochloric acid (amino acid analysis).

Example 23

10 Synthesis of a peptide derivative of hyaluronic acid containing a peptide having the sequence Phe-Val-Glu-Tyr-Leu

- 50% of the carboxy functions are transformed into amides of hyaluronic acid with the peptide - 50% of the carboxy functions are salified with sodium

- 5.83 grams of the active ester obtained as in Example 2 corresponding to 10 mEq of a monomeric unit are solubilized in 290 ml of N-methylpyrrolidone at 25°C. To this solution are added, with stirring, 3.46 grams of a peptide having the sequence Phe-Val-Glu-Tyr-(5 mEq) solubilized in 20 ml of N-methyl-The mixture is stirred for 2 hours and pyrrolidone. then 100 ml of a 2% solution of sodium chloride in deionized water are added. The addition to this reaction mixture of 800 ml of acetone causes the formation of a precipitate, which is filtered and washed three times with 100 ml of acetone and then vacuum-dried for 24 hours at 30°C.
- 5.4 grams of the desired product are thus obtained.

 30 Quantitative determination of the amide groups is performed by analysing the amino acid content after acid hydrolysis in 6N hydrochloric acid (amino acid analysis).

25

28

Example 24

Synthesis of a peptide derivative of HYAFF 11p75 containing a peptide having the sequence Gly-Arg-Gly-Asp-Ser-Tyr-

-25% of the carboxy functions are transformed into amides of hyaluronic acid with the peptide 75% of the carboxy functions are esterified with benzyl alcohol

- 4.8 grams of the active ester obtained as in 10 Example 11 corresponding to 10 mEq of a monomeric unit are solubilized in 240 ml of N-methylpyrrolidone at 25°C. To this solution are added, with stirring, 1.85 grams of a peptide having the sequence Gly-Arg-Gly-Asp-Ser-Tyr (2.5 mEq) solubilized in 10 ml of N-methyl-15 pyrrolidone. The mixture is stirred for 2 hours and then 100 ml of a 2% solution of sodium chloride in deionized water are added. The addition to this reaction mixture of 800 ml of acetone causes the formation of a precipitate, which is filtered and washed 20 three times with 100 ml of acetone and then vacuum-dried for 24 hours at 30°C.
 - 5.0 grams of the desired product are thus obtained. Quantitative determination of the amide groups is performed by analysing the amino acid content after acid hydrolysis in 6N hydrochloric acid (amino acid analysis).

25

30

Example 25

Synthesis of a peptide derivative of HYAFF 7p50 containing a peptide having the sequence Gly-Arg-Gly-Asp-Val-Tyr

-50% of the carboxy functions are transformed into amides of hyaluronic acid with the peptide -50% of the carboxy functions are esterified with ethyl alcohol

- 4.95 grams of the active ester obtained as in 10 Example 10 corresponding to 10 mEg of a monomeric unit are solubilized in 250 ml of N-methylpyrrolidone at 25°C. To this solution are added, with stirring, 3.765 grams of a peptide having the sequence Gly-Arg-Gly-Asp-Val-Tyr (5 mEq) solubilized in 20 ml of N-methyl-15 pyrrolidone. The mixture is stirred for 2 hours and then 100 ml of a 2% solution of sodium chloride in deionized water are added. The addition to this reaction mixture of 800 ml of acetone causes the formation of a precipitate, which is filtered and washed 20 three times with 100 ml of acetone and then vacuum-dried for 24 hours at 30°C.
 - 5.1 grams of the desired product are thus obtained. Quantitative determination of the amide groups is performed by analysing the amino acid content after acid hydrolysis in 6N hydrochloric acid (amino acid analysis).

Example 26

Preparation of a partial thiofuran thioester of hyaluronic acid sodium salt - 10% of the carboxy groups are involved in the formation of the thioester -90% of the carboxy groups are salified with sodium

6.13 grams of the active ester obtained as in Example 2 corresponding to 10 mEq of a monomeric unit are solubilized in 305 ml of N-methylpyrrolidone at

25°C. To this solution are added, with stirring, 79.4 ml of thiofuran. The mixture is stirred for 2 hours and then 100 ml of a 2% solution of sodium chloride in deionized water is added. The addition to this reaction mixture of 800 ml of acetone causes the formation of a precipitate, which is filtered and washed three times with 100 ml of acetone and then vacuum-dried for 24 hours at 30°C.

6.3 grams of the desired product are thus obtained.
10 Quantitative determination of the amide groups is performed by analysing the thiofuran content after basic hydrolysis.

Example 27 Sponges

One gram of the heptyl amide of HA with a molecular weight of 200 Kda, wherein the carboxy groups are employed in the substitution reaction, are dissolved in 10 ml of dimethylsulfoxide. The solution is homogenized to form a mixture containing 30 grams of NaCl, 1.3 grams of bicarbonate of soda and 1 gram of citric acid.

Once the final mixture is completely homogenized, it is passed between two rollers placed at a suitable distance from one another and turning in opposite directions. A layer of material is obtained by passing the mixture between them on a silicone support. The layer is then cut to the desired dimensions and the silicone support is removed. The layer is washed thoroughly with water and dried. It can then be sterilized with gamma rays.

WO 95/24429 PCT/EP95/00932

31

Example 28 Films

A solution is prepared by solubilizing the N-benzyl amide of HA in dimethylsulfoxide at a concentration of 180 mg/ml.

By means of a stratifier, a thin layer of solution is spread on a glass sheet; the thickness must be 10 times greater than the final thickness of the film. The glass sheet is immersed in ethanol, which absorbs the dimethylsulfoxide, but which does not solubilize the HA N-benzyl amide, which becomes solid. The film is detached from the glass sheet, repeatedly washed with ethanol, then with water, and then again with ethanol.

The resulting sheet is dried in a press for 48 15 hours at 30°C.

The invention being thus described, it is obvious that the same can be modified in various ways. Such modifications are not to be considered as departures from the spirit and scope of the present invention, and any modifications that would appear obvious to one skilled in the art are to be considered as coming within the scope of the following claims.

10

WHAT IS CLAIMED IS:

 An active ester of a carboxy polysaccharide or a semisynthetic derivative of a carboxy polysaccharide,

wherein all or part of the carboxy groups thereof are esterified with an alcohol selected from the group consisting of an aromatic alcohol, a substituted aromatic alcohol, an aromatic heterocyclic alcohol, a substituted aromatic heterocyclic alcohol, an N-hydroxylamine, and a combination thereof,

wherein when only part of the carboxy groups of said carboxy polysaccharide or said semisynthetic derivative of said carboxy polysaccharide are esterified, the remaining carboxy groups are salified with a member selected from the group consisting of a quaternary ammonium salt, an alkaline metal, an alkaline earth metal, and a combination thereof.

- 2. The active ester according to claim 1, wherein said alcohol is an aromatic alcohol.
- 3. The active ester according to claim 2, wherein20 said aromatic alcohol is a substituted aromatic alcohol.
 - 4. The active ester according to claim 3, wherein said substituted aromatic alcohol is selected from the group consisting of a fluoro-substituted aromatic alcohol, a chloro-substituted aromatic alcohol, and a nitro-substituted aromatic alcohol.
 - 5. The active ester according to claim 4, wherein said substituted aromatic alcohol is selected from the group consisting of pentafluorophenol, pentachlorophenol, 4-nitrophenol, and a combination thereof.

- 6. The active ester according to claim 1, wherein said alcohol is an aromatic heterocyclic alcohol.
- 7. The active ester according to claim 6, wherein said aromatic heterocyclic alcohol is selected from the group consisting of a benzotriazoline alcohol, a thiophene alcohol, a hydroxypyridine alcohol, a pyrazoline alcohol, and a combination thereof.
- 8. The active ester according to claim 6, wherein said aromatic heterocyclic alcohol is selected from the group consisting of 2-hydroxypyridine, 3-hydroxypyridine, 3,4-dihydro-4-oxobenzotriazine-3-ol, 4-hydroxy-2,5-diphenyl-3(2H)thiophenone-1,1-dioxide, 3-phenyl-1-(p-nitrophenyl)-2-pyrazoline-5-one, 3-methyl-1-(p-nitrophenyl)-2-pyrazoline-5-one, and a combination thereof.
 - 9. The active ester according to claim 1, wherein said alcohol is an N-hydroxylamine.
- 10. The active ester according to claim 9, wherein said N-hydroxylamine is selected from the group consisting of N-hydroxysuccinimide, N-hydroxyphthalimide, and a combination thereof.
 - 11. The active ester according to claim 1, wherein said quaternary ammonium salt is a tetraalkylammonium salt.
- 25 12. The active ester according to claim 11, wherein said tetraalkylammonium salt is a tetrabutylammonium salt.
- 13. The active ester according to claim 1, wherein said carboxy polysaccharide or semisynthetic derivative30 thereof is selected from the group consisting of a

glycosaminoglycan, alginic acid, gellan, carboxymethylcellulose, carboxymethylchitin, carboxymethylamide, and a partial ester thereof.

- 14. The active ester according to claim 1, wherein5 said glycosaminoglycan is hyaluronic acid.
- 15. The active ester according to claim 1, wherein said synthesized active ester is tetrabutylammonium salt selected from the consisting of the tetrabutylammonium salt 10 glycosaminoglycan, the tetrabutylammonium of alginic acid, the tetrabutylammonium salt of gellan, the tetrabutylammonium salt of carboxymethylcellulose, the tetrabutyl ammonium salt of carboxymethylchitin, and the tetrabutylammonium salt of carboxymethylamide.
- 15 16. The active ester according to claim 1, wherein said semisynthetic derivative of said carboxy polysaccharide is a partial ester of said carboxy polysaccharide.
- 17. The active ester according to claim 16, 20 wherein said partial ester is an ester with an alcohol selected from the group consisting of an aliphatic alcohol, an araliphatic alcohol, a cycloaliphatic alcohol, a heterocyclic alcohol, and a combination thereof.
- 25 18. The active ester according to claim 17, wherein said aliphatic alcohol contains between 2 and 34 carbon atoms.
- 19. The active ester according to claim 17, wherein said partial ester is an ester with ethyl 30 alcohol.

- 20. The active ester according to claim 17, wherein said partial ester is an ester with an araliphatic alcohol.
- 21. The active ester according to claim 20, 5 wherein said araliphatic alcohol is benzyl alcohol.
- 22. An active ester according to claim 1, selected from the group consisting of a pentafluorophenyl ester of hyaluronic acid with 5% of its carboxy groups involved in the formation of the active ester and wherein the remaining 95% of the carboxy groups are 10 salified with tetrabutylammonium; a pentafluorophenyl ester of hyaluronic acid with 10% of its carboxy groups involved in the formation of the active ester and wherein the remaining 90% of the carboxy groups are 15 salified with tetrabutylammonium; a pentafluorophenyl ester of hyaluronic acid with 25% of its carboxy groups involved in the formation of the active ester and wherein the remaining 75% of the carboxy group are salified with tetrabutylammonium; a pentafluorophenyl 20 ester of hyaluronic acid with 50% of its carboxy groups involved in the formation of the active ester and wherein the remaining 50% of the carboxy groups are salified with tetrabutylammonium; a pentafluorophenyl ester of hyaluronic acid with 75% of its carboxy groups 25 involved in the formation of the active ester and wherein the remaining 25% of the carboxy groups are salified with tetrabutylammonium; a pentafluorophenyl ester of hyaluronic acid with 100% of its carboxy groups involved in the formation of the active ester; a 4-nitrophenyl ester of hyaluronic acid with 25% of its 30 carboxy groups involved in the formation of the active ester and wherein the remaining 75% of the carboxy groups are salified with tetrabutylammonium; 2,5-diphenyl-thiophene-4-yl-3(2H)-one-1,1-dioxide ester 35 of hyaluronic acid with 50% of its carboxy groups

involved in the formation of the active ester and wherein the remaining 50% of the carboxy groups are salified with tetrabutylammonium, a pentafluorophenyl ester of alginic acid with 20% of its carboxy groups involved in the formation of the active ester and wherein the remaining 80% of the carboxy groups are salified with tetrabutylammonium; a pentafluorophenyl ester of the ethyl ester of hyaluronic acid p50 with 25% of its carboxy groups involved in the formation of the active ester and wherein 50% of the carboxy groups are esterified with ethanol and the remaining 25% of the carboxy groups are salified with tetrabutylammonium; and a pentafluorophenyl ester of the benzyl ester hyaluronic acid p75 wherein 25% of the carboxy groups are involved in the formation of the active ester and the remaining 75% of the carboxy groups are esterified with benzyl alcohol.

- 23. A process for producing an active ester according to claim 1, comprising reacting a tetraalkylammonium salt of said carboxy polysaccharide or said semisynthetic derivative of said carboxy polysaccharide with a reactive derivative of an alcohol to be bound to the carboxyl groups thereof in an aprotic solvent at a temperature of between about 0 and about 60°C.
- 24. The process according to claim 23, wherein said reactive derivative of an alcohol is selected from the group consisting of a trifluoroacetate, a carbonate, an oxalate, a sulfite, and a phosphite of said alcohol.
- 30 25. The process according to claim 23, wherein said reactive derivative of an alcohol is a member selected from the group consisting of 4-nitrophenyl trifluoroacetate, pentafluorophenyl trifluoroacetate, di-pentafluorophenyl sulfite, Di-(N-succinimidyl)

10

15

20

- c a r b o n a t e , a n d 4,6-diphenylthiene[3,4-d]-1,3-dioxol-2-one 5,5dioxide.
- 26. The process according to claim 23, wherein said aprotic solvent is selected from the group consisting of dimethylsulfoxide, N-methylpyrrolidone, and N,N-dimethylformamide.
- 27. The process according to claim 23, wherein said tetraalkylammonium salt is a tetrabutylammonium salt.
- 10 28. Use of said active ester according to claim 1 for the preparation of a modified carboxy polysaccharide or a modified semisynthetic derivative of a carboxy polysaccharide.
- 29. Use of said active ester according to claim 15 28, wherein said modified carboxy polysaccharide or said modified semisynthetic derivative of a carboxy polysaccharide is an ester, thioester, or amide.
 - 30. Use of said active ester according to claim 29, wherein said amide is formed by reaction of said active ester of said carboxy polysaccharide or said semisynthetic derivative of said carboxy polysaccharide with a member selected from the group consisting of an amine, an amino acid, a peptide, and a protein.
- 31. Use of said active ester according to claim 25 30, wherein said amine is selected from the group consisting of a primary amine, an aliphatic amine, an araliphatic amine, a substituted aliphatic amine, and a substituted araliphatic amine.

- 32. Use of said active ester according to claim 30, wherein said amino acid, peptide, or protein is biologically active.
- 33. An amide derivative of hyaluronic acid seclected from the group consisting of:

an N-ethyl amide of hyaluronic acid with 10% of its carboxy groups involved in the formation of the amide and the remaining 90% of its carboxy groups salified with sodium:

an N-benzyl amide of hyaluronic acid with 50% of its carboxy groups involved in the formation of the amide and the remaining 50% of its carboxy groups salified with sodium:

an amide derivative of hyaluronic acid with arginine wherein 100% of the carboxy groups are involved in the formation of the amide;

- a peptide derivative of the 50% ethyl ester of hyaluronic acid with a peptide inhibitor of the fraction of fibronectin having the sequence
- 20 H-Arg-Gly-Asp-OH with 50% of its carboxy functions esterified with ethanol, 25% of its carboxy functions involved in the formation of the amide with the peptide, and the remaining 25% of its carboxy functions salified with sodium; and
- a peptide derivative of the benzyl ester of hyaluronic acid p75 with a peptide inhibitor of fibrinolysis having the sequence H-Gly-Pro-Arg-OH with 75% of its carboxy functions esterified with benzyl alcohol and 25% of its carboxy functions involved in the formation of the amide with the peptide.
 - 34. A process for the synthesis of an amide according to any one of claims 29-33, comprising reacting an active ester of a carboxy polysaccharide or an active ester of a semisynthetic derivative of a carboxy polysaccharide with an amine, an amino acid, a

20

peptide, or a protein in an aprotic solvent at a temperature of between about 0 and 60°C.

- 35. Use of an active ester, a modified polysaccharide, a modified semisynthetic derivative of a polysaccharide, or an amide according to any one of claims 1-22 or 39 in the biomedical and pharmaceutical fields.
- 36. The use according to claim 35 for the preparation of cosmetic articles, health care articles,surgical articles, and diagnostic kits.
 - 37. The use according to claim 36, to prepare microcapsules, microspheres, threads, films, gauzes, and sponges.
- 38. Use of an active ester, modified polysaccharide, modified semisynthetic derivative of a polysaccharide, or an amide according to any one of claims 35-37 in tissue repair.
 - 39. Use of a modified polysaccharide, modified semisynthetic derivative of a polysaccharide, or an amide according to any one of claims 35-37 in a controlled release system for a biologically or pharmacologically active substance, wherein said substance is selected from the group consisting of an amino acid, a peptide, and a protein.
- 25 40. A modified carboxy polysaccharide, or a modified semisynthetic derivative of a carboxy polysaccharide, prepared from said active ester of claim 1.

INTERNATIONAL SEARCH REPORT

Inter. nal Application No PCT/EP 95/00932

IFICATION OF SUBJECT MATTER		
C08B37/00		
	ssification and IPC	
	eation symbols)	
CO8B	7.07	
tion searched other than minimum documentation to the extent the	at such documents are included in the fields	searched
late have consulted during the international search (name of data)	ase and, where practical, search terms used)
and the commended the life are interinational season (similar or many)	(1)	,
MENTS CONSIDERED TO BE RELEVANT	-	I Balancet to plain No.
Citation of document, with indication, where appropriate, of the	relevant passages	Relevant to claim No.
WO,A,92 20349 (GENZYME) 26 Nover see page 6, line 32 - page 7, l	mber 1992 ine 3	1-40
April 1959	Γ AL.) 7	1-40
EP,A,O 251 905 (FIDIA) 7 January cited in the application see page 23, line 10 - line 56	y 1988	1-40
GB,A,1 507 964 (AKADEMIE DER WISSENSCHAFTEN DER DDR) 19 Apri see claim 7	1 1978	
WO,A,86 04145 (UNIVERSITY OF NET 17 July 1986	W MEXICO)	
see page 7, paragraph SECOND		
her documents are listed in the continuation of box C.	Patent family members are listed	d in annex.
tegories of cited documents:	"T" later document published after the ir	nternational filing date
ent defining the general state of the art which is not tered to be of particular relevance	cited to understand the principle or	theory underlying the
document but published on or after the international date	"X" document of particular relevance; the	ot be considered to
ent which may throw doubts on priority claim(s) or	involve an inventive step when the e	document is taken alone ne claimed invention
n or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or	cannot be considered to involve an document is combined with one or	inventive step when the more other such docu-
means ent published prior to the international filing date but	in the art.	
han the priority date claimed	•	
	7. 08. 95	areas and Aregina is
	Authorized officer	
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.	Lensen, H	
	co International Patent Classification (IPC) or to both national classification (IPC) or to both national classification system followed by classific CO8B Bron searched other than minimum documentation to the extent the state of the appropriate of the extent that the state of the appropriate of t	conternational Patent Classification (IPC) or to both national classification and IPC SEARCHED Incumentation searched (classification system followed by classification symbols) COSB Lonsearched other than maximum documentation to the extent that such document are included in the fields attal base consulted during the international search (name of data base and, where practical, search terms used LENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages WO, A, 92 20349 (GENZYME) 26 November 1992 see page 6, line 32 - page 7, line 3 US, A, 2 881 161 (RUDOLF KÖHLER ET AL.) 7 April 1959 see column 2, line 5 - line 46 EP, A, 0 251 905 (FIDIA) 7 January 1988 cited in the application see page 23, line 10 - line 56 GB, A, 1 507 964 (AKADEMIE DER WISSENSCHAFTEN DER ODR) 19 April 1978 see claim 7 WO, A, 86 04145 (UNIVERSITY OF NEW MEXICO) 17 July 1986 see page 7, paragraph SECOND Are documents are listed in the continuation of box C. Legories of cited documents: or other preclaim the promptly claim() or enter secting to an oral disclosure, use, exhibition or means and her priority date claimed actual completion of the international filing date but and her priority date claimed To actual completion of the international search July 1995 Authorized officer Authorized officer Authorized officer Legories of the ISA No. 1280 HV Rijavist, 1281 Splenthaan 2 NI. 1280 HV Rijavist,

Form PCT/ISA/218 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Inter mal Application No
PCT/EP 95/00932

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9220349	26-11-92	AU-A- 2143 EP-A- 0587 JP-T- 6508	715 23-03-94
US-A-2881161	07-04-59	NONE	ete een teer seer een seer teer seer seer seer teen teen teen teen seer seer seer teen daar daar man
EP-A-251905	07-01-88	AT-T- 1130 AU-B- 6513 AU-A- 7008 AU-B- 6029 CN-B- 10260 DE-D- 37500 DE-T- 37500 EP-A- 06099 IL-A- 829 JP-A- 630334 NO-B- 1750 US-A- 54162 US-A- 52644 US-A- 53366 US-A- 51478 ZA-A- 87049	304 04-08-94 491 16-05-91 301 01-11-90 001 28-09-94 710 08-12-94 710 16-03-95 968 10-08-94 943 27-02-94 401 13-02-88 059 16-05-94 205 16-05-95 422 23-11-93 568 09-08-94 861 15-09-92
GB-A-1507964	19-04-78	CH-A- 6227 SE-A- 76087	
 WO-A-8604145	17-07-86	US-A- 47328 DE-C- 35903 DE-T- 35903 GB-A,B 21814 JP-T- 625014	392 14-01-93 392 27-10-88 433 23-04-87

Form PCT/ISA/210 (patent family snnex) (July 1992)